Randomized Trialhigh evidence
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
Nature medicine·March 1, 2026·PMID 41772149
Why it mattersCombining an agent that preserves muscle while reducing fat with a GLP-1 agonist could address concerns about lean mass loss during weight reduction, potentially improving long-term metabolic health and functional outcomes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled